Status:
UNKNOWN
Omega-3 Oil Use in COVID-19 Patients in Qatar
Lead Sponsor:
Hamad Medical Corporation
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
COVID-19 infection has been widely spread since December 2019 and causing many comorbidities and fatalities. The most common clinical presentation of COVID-19 patients admitted to ICUs is respiratory ...
Detailed Description
The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) due to a novel coronavirus (COVID-19) has emerged from Wuhan, China in late December 2019 and spread rapidly worldwide. Unt...
Eligibility Criteria
Inclusion
- adult ICU patients ≥18 years
- confirmed COVID-19 infection
- on-Oxygen support (mechanical ventilation, face masks, nasal cannula, etc.)
- Previous history of omega-3-oil with discontinuation of at least 1 month prior to admission
Exclusion
- soya bean oil allergy
- fish allergy
- peanut allergy
- fish oil allergy
- pregnant women
- Continuous use of Omega-3-oil till admission
Key Trial Info
Start Date :
December 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 24 2021
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT04836052
Start Date
December 24 2020
End Date
December 24 2021
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Corporation
Doha, DC, Qatar, 3050